dc.contributor.author |
Sari-Ak, D
|
|
dc.contributor.author |
Alomari, O
|
|
dc.contributor.author |
Shomali, RA
|
|
dc.contributor.author |
Lim, J
|
|
dc.contributor.author |
Thimiri Govindaraj, Deepak B
|
|
dc.date.accessioned |
2023-03-17T08:45:27Z |
|
dc.date.available |
2023-03-17T08:45:27Z |
|
dc.date.issued |
2022-12 |
|
dc.identifier.citation |
Sari-Ak, D., Alomari, O., Shomali, R., Lim, J. & Thimiri Govindaraj, D.B. 2022. Advances in CRISPR-Cas9 for the Baculovirus Vector System: A systematic review. <i>Viruses-Basel.</i> http://hdl.handle.net/10204/12679 |
en_ZA |
dc.identifier.issn |
1999-4915 |
|
dc.identifier.uri |
https://doi.org/10.3390/v15010054
|
|
dc.identifier.uri |
http://hdl.handle.net/10204/12679
|
|
dc.description.abstract |
The baculovirus expression vector systems (BEVS) have been widely used for the recombinant production of proteins in insect cells and with high insert capacity. However, baculovirus does not replicate in mammalian cells; thus, the BacMam system, a heterogenous expression system that can infect certain mammalian cells, was developed. Since then, the BacMam system has enabled transgene expression via mammalian-specific promoters in human cells, and later, the MultiBacMam system enabled multi-protein expression in mammalian cells. In this review, we will cover the continual development of the BEVS in combination with CRPISPR-Cas technologies to drive genome-editing in mammalian cells. Additionally, we highlight the use of CRISPR-Cas in glycoengineering to potentially produce a new class of glycoprotein medicines in insect cells. Moreover, we anticipate CRISPR-Cas9 to play a crucial role in the development of protein expression systems, gene therapy, and advancing genome engineering applications in the future. |
en_US |
dc.format |
Fulltext |
en_US |
dc.language.iso |
en |
en_US |
dc.relation.uri |
https://www.mdpi.com/1999-4915/15/1/54 |
en_US |
dc.source |
Viruses-Basel |
en_US |
dc.subject |
Baculovirus Vector System |
en_US |
dc.subject |
BEVS |
en_US |
dc.subject |
CRISPR-Cas9 |
en_US |
dc.subject |
Complex Glycosylation |
en_US |
dc.subject |
MultiBac |
en_US |
dc.title |
Advances in CRISPR-Cas9 for the Baculovirus Vector System: A systematic review |
en_US |
dc.type |
Article |
en_US |
dc.description.pages |
17 |
en_US |
dc.description.note |
Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
en_US |
dc.description.cluster |
Next Generation Health |
en_US |
dc.description.impactarea |
Synthetic Nanobiotech Biomachs |
en_US |
dc.identifier.apacitation |
Sari-Ak, D., Alomari, O., Shomali, R., Lim, J., & Thimiri Govindaraj, D. B. (2022). Advances in CRISPR-Cas9 for the Baculovirus Vector System: A systematic review. <i>Viruses-Basel</i>, http://hdl.handle.net/10204/12679 |
en_ZA |
dc.identifier.chicagocitation |
Sari-Ak, D, O Alomari, RA Shomali, J Lim, and Deepak B Thimiri Govindaraj "Advances in CRISPR-Cas9 for the Baculovirus Vector System: A systematic review." <i>Viruses-Basel</i> (2022) http://hdl.handle.net/10204/12679 |
en_ZA |
dc.identifier.vancouvercitation |
Sari-Ak D, Alomari O, Shomali R, Lim J, Thimiri Govindaraj DB. Advances in CRISPR-Cas9 for the Baculovirus Vector System: A systematic review. Viruses-Basel. 2022; http://hdl.handle.net/10204/12679. |
en_ZA |
dc.identifier.ris |
TY - Article
AU - Sari-Ak, D
AU - Alomari, O
AU - Shomali, RA
AU - Lim, J
AU - Thimiri Govindaraj, Deepak B
AB - The baculovirus expression vector systems (BEVS) have been widely used for the recombinant production of proteins in insect cells and with high insert capacity. However, baculovirus does not replicate in mammalian cells; thus, the BacMam system, a heterogenous expression system that can infect certain mammalian cells, was developed. Since then, the BacMam system has enabled transgene expression via mammalian-specific promoters in human cells, and later, the MultiBacMam system enabled multi-protein expression in mammalian cells. In this review, we will cover the continual development of the BEVS in combination with CRPISPR-Cas technologies to drive genome-editing in mammalian cells. Additionally, we highlight the use of CRISPR-Cas in glycoengineering to potentially produce a new class of glycoprotein medicines in insect cells. Moreover, we anticipate CRISPR-Cas9 to play a crucial role in the development of protein expression systems, gene therapy, and advancing genome engineering applications in the future.
DA - 2022-12
DB - ResearchSpace
DP - CSIR
J1 - Viruses-Basel
KW - Baculovirus Vector System
KW - BEVS
KW - CRISPR-Cas9
KW - Complex Glycosylation
KW - MultiBac
LK - https://researchspace.csir.co.za
PY - 2022
SM - 1999-4915
T1 - Advances in CRISPR-Cas9 for the Baculovirus Vector System: A systematic review
TI - Advances in CRISPR-Cas9 for the Baculovirus Vector System: A systematic review
UR - http://hdl.handle.net/10204/12679
ER -
|
en_ZA |
dc.identifier.worklist |
26474 |
en_US |